ClinicalTrials.gg
CompletedNCT02182258Updated Jul 18, 2014

Safety and Tolerability Study of BIBF 1120 as Intravenous Infusion and Absolute Bioavailability of BIBF 1120 as Soft Gelatine Capsule in Healthy Subjects

A Phase 1 interventional study of BIBF 1120 soft gelatine capsule and BIBF 1120 intravenous solution in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-18.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

The primary objective of this trial was to assess the safety and tolerability of BIBF 1120 administered as intravenous (iv) infusions of 1, 3, 10, and 20 mg, and to assess the absolute bioavailability of orally administered 100 mg BIBF 1120 as soft gelatine capsules. A secondary objective was the exploration of the pharmacokinetic (PK) of BIBF 1120 after single iv dosing, including dose proportionality.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy males according to the following criteria:

  1. Based upon a complete medical history, including the physical examination, vital signs (blood pressure, pulse rate), 12-lead , and clinical laboratory tests
  2. Age ≥18 years and ≤50 years
  3. (BMI) ≥18.5 and ≤29.9 kg/m2
  4. Signed and dated written prior to admission to the study, in accordance with GCP and local legislation

Exclusion criteria

Exclusion Criteria:

  1. Any finding from medical examination (including blood pressure, pulse rate, ) deviating from normal and of clinical relevance
  2. History of or current gastrointestinal, hepatic (including Gilbert's syndrome and history of increases) renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  3. History of relevant orthostatic hypotension, fainting spells, and blackouts
  4. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  5. Chronic or relevant acute infections
  6. History of allergy/ (including drug allergy or its ) which is deemed relevant to the trial as judged by the investigator
  7. History of any bleeding disorder including prolonged or habitual bleeding, other haematologic disease or cerebral bleeding (e.g. after a car accident) or commotio cerebri
  8. Intake of drugs with a long half-life (>24 h) within 1 month prior to administration or during the trial
  9. Use of any drugs which might influence the results of the trial within 14 days prior to administration or during the trial
  10. Participation in another trial with an drug within 2 months prior to administration or during the trial
  11. Smoker (>10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from smoking on study days
  12. Alcohol abuse (>30 g/day)
  13. Drug abuse
  14. Blood donation (>150 mL within 4 weeks prior to administration or during the trial)
  15. Excessive physical activities within 5 days prior to administration or during the trial
  16. Any laboratory value outside the reference range that is of clinical relevance
  17. Male subjects refusing to minimise the risk of female partners becoming pregnant from the first dosing day until 3 months after completion of the study. Acceptable methods of for male volunteers include vasectomy no less than 3 months prior to administration, barrier contraception, or a medically accepted contraceptive method. Acceptable methods of contraception for female partners of male volunteers include intra-uterine device, tubal ligation, hormonal contraceptive for at least 2 months and diaphragm with spermicide.
  18. Homozygous genotype status for UGT1A1*28, *60 (Gilbert polymorphisms)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single
Enrollment
30 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo ampoule

  • Active comparator
    BIBF 1120 intravenous

    Drug: BIBF 1120 intravenous solution

  • Experimental
    BIBF 1120 capsule

    Drug: BIBF 1120 soft gelatine capsule

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)

    Time frame: Up to 48 hours after drug administration

  2. Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point (AUC0-tz)

    Time frame: Up to 48 hours after drug administration

Secondary outcomes

  1. Maximum measured concentration of the analyte in plasma (Cmax)

    Time frame: Up to 48 hours after drug administration

  2. Time from dosing to the maximum concentration of the analyte in plasma (tmax)

    Time frame: Up to 48 hours after drug administration

  3. %AUCtz-∞ (calculated from AUC0-∞ and AUC0-tz )

    Time frame: Up to 48 hours after drug administration

  4. Terminal rate constant in plasma (λz)

    Time frame: Up to 48 hours after drug administration

  5. Terminal half-life of the analyte in plasma (t1/2)

    Time frame: Up to 48 hours after drug administration

  6. Mean residence time of the analyte in the body after oral administration (MRTpo)

    Time frame: Up to 48 hours after drug administration

  7. Mean residence time of the analyte in the body after iv administration (MRT)

    Time frame: Up to 48 hours after drug administration

  8. Apparent clearance of the analyte in plasma after extravascular administration (CL/F)

    Time frame: Up to 48 hours after drug administration

  9. Apparent clearance of the analyte in plasma after intravenous administration (CL)

    Time frame: Up to 48 hours after drug administration

  10. Apparent volume of distribution during the terminal phase λz following an extravascular dose (Vz/F)

    Time frame: Up to 48 hours after drug administration

  11. Apparent volume of distribution during the terminal phase λz following an intravenous dose (Vz)

    Time frame: Up to 48 hours after drug administration

  12. Apparent volume of distribution at steady-state following an intravenous dose (Vss)

    Time frame: Up to 48 hours after drug administration

  13. Amount of analyte that is eliminated in urine within the time interval t1 to t2 (Aet1-t2)

    Time frame: Up to 48 hours after drug administration

  14. Fraction of analyte excreted in urine within the time interval t1 to t2, in percentage of dose (fet1-t2)

    Time frame: Up to 48 hours after drug administration

  15. Renal clearance of analyte within the time interval t1 to t2 (CLR,t1-t2)

    Time frame: Up to 48 hours after drug administration

  16. Change from baseline in physical examination

    Time frame: Baseline, day 46

  17. Change from baseline in vital signs (BP, PR)

    Time frame: Baseline, day 46

  18. Change from baseline in 12-lead ECG (electrocardiogram)

    Time frame: Baseline, day 46

  19. Change from baseline in clinical laboratory test (hematology, clinical chemistry and urinalysis)

    Time frame: Baseline, day 46

  20. Number of Participants with Serious and Non-Serious Adverse Events

    Time frame: Up to day 46

  21. Assessment of tolerability by investigator on a four point scale (good, satisfactory, not satisfactory, bad)

    Time frame: Up to day Day 46

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2009 and a primary completion of Aug 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2014
First posted
Jul 8, 2014
Start
Jun 2009
Primary completionActual
Aug 2009
Last update
Jul 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02182258
Responsible party
Sponsor
First posted
Jul 8, 2014
Start date
Jun 2009
Primary completion
Aug 2009
Last update
Jul 18, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion